Quantitative analysis confirmed that the combination of FAK and MEK inhibitors resulted in a statistically significant reduction in tumor size relative to the monotherapy arms, underscoring the potential of this combination therapy in effectively targeting glioblastoma (Figure 8C). The gene discussed is PTK2; the disease is glioblastoma.